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INTRODUCTION
Since the enactment of the policy of separating prescrip-
tion and dispensing in Korea in 2000, disputes on generic
substitution and generic prescription have not subsided be-
tween physicians and the Korean government. In the U.S.
and many EU countries, the frequency of generic prescrip-
tion is known to be higher than 50% of the total number of
prescriptions issued. The US FDA has been consistent in main-
taining their position that the generics coded as “AB” in the
Orange Book of FDA (http://www.fda.gov/cder/ob/default.
htm) are therapeutically equivalent without exception, even
in the case of drugs with narrow therapeutic indices (NTI)
(1). However, the attempt to introduce the individual bioe-
quivalence (BE) in early 2000s seems to reflect serious recon-
sideration of the current average BE guidance within the
FDA, although only a few individual BE study reports had
actually been filed. Despite the FDA’s official position, physi-
cians have long been raising questions about the efficacy and
safety of generics, especially for NTI drugs (2-9).
In this context, the author simulated several scenarios of
generic substitution to predict the changes in exposure (area
under the drug concentration-time curve; AUC) in 5,000
patients, using the R program (http://www.r-project.org/).
The scenarios had different number of generics per original
(branded or innovator drug) and different relative bioavail-
ability (BA) in comparison with the original.
MATERIALS AND METHODS
Basic models for the AUC of the original and generics
To simulate the generic substitution, we made several ass-
umptions concerning the AUCs of the original and generic
formulations of an active ingredient named Drug X. The first
was about the between subject variability (BSV) of the BA
(AUC). Because the BSV is related with the difference between
each patient’s capacity to eliminate drug molecules (i.e., genet-
ic differences in the metabolic activity, individual differences
in the GFR, etc), it varies with what the active ingredient is,
but not with what the manufacturing company is. Therefore,
the BSV for Drug X was assumed be normally distributed
with the mean value 0 and variance 0.04 (0.22) without regard
to the formulations. The residual variability (RV) for the orig-
inal was then assumed to be 10% and the RV for the generics
varied between scenarios. The AUCs were assumed to follow
log-normal distribution. The following equations summarize
these assumptions.
Indiv Mean AUCOri_i=Pop Mean AUCOri (=100)×exp (η i),
η i~N (0, 0.22) (1)
Indiv Mean AUCGen1_i=Pop Mean AUCGen1×exp (η i) (2-1)
Indiv Mean AUCGen2_i=Pop Mean AUCGen2×exp(η i) (2-2)
In the equation (1), Pop Mean AUCOri (the mean AUC of
the original formulation of Drug X in the patient population),
was assumed to be 100 for all scenarios. No units for AUC
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Simulation of the AUC Changes after Generic Substitution in Patients
To address the debate on the safety of generic substitution quantitatively, the author
compared the change in AUC in virtual patients who were simulated for several dif-
ferent scenarios of generic substitution. In four scenarios of original (branded) to
generic and generic to generic substitution, 5,000 virtual patients were simulated per
scenario using the programming software R. The mean population AUC of gener-
ics ranged from 90-110% (scenarios A and B) and 80-123.5% (scenarios C and D)
of the AUC of the original. Those patients who had an AUC change (ratio) as a result
of drug substitution of less than 0.67 or greater than 1.5 were considered to be in
potential danger due to the substitution. We found that less than 6% of patients fell
outside of the cutoff range of 0.67-1.5 as a result of original to generic substitution.
However, in the case of generic to generic substitution, the proportion was as high
as 9-12%. This alerts us to the potential danger of generic substitution, especially
for drugs with narrow therapeutic indices.
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and (2-2), Pop Mean AUCGen1 and Pop Mean AUCGen2 denote
mean population AUCs of two different generics (Gen1 and
Gen2). Gen1 and Gen2 are those which are randomly select-
ed from many different generics of Drug X, produced by differ-
ent companies in each simulation scenario. In equations (1),
(2-1) and (2-2), the individual mean AUCs in the i th simu-
lated patient (Indiv Mean AUCOri_i, Indiv Mean AUCGen1_i
and Indiv Mean AUCGen2_i) share the same η i (BSV), which
follows a Gaussian distribution of mean 0 and variance 0.04
as mentioned above. Therefore, whatever value the η i may
be, it does not influence the AUC ratios of switched formu-
lations in an individual patient.
Equations (3) and (4) were used to produce the AUC for the
i th simulated patient after taking the original (AUCOri_ij) and
generic (AUCGen_i) formulations of Drug X.
AUCOri_ij=Indiv Mean AUCOri_i×(1+ε Ori_ij), ε Ori_ij~N (0, 0.12)
(3)
AUCGen1_i=Indiv Mean AUCGen1_i×(1+ε Gen1_i), ε Gen1_i~N (0,
ω Gen12) (4-1)
AUCGen2_i=Indiv Mean AUCGen2_i×(1+ε Gen2_i), ε Gen2_i~N (0,
ω Gen22) (4-2)
Because the simulated patient was assumed to take the orig-
inal formulation on two separate occasions, the subscript j in
equation (3) corresponds to 1 (first time) or 2 (second time).
The RV was described using the symbol ε . The ε Ori_ij was as-
sumed to follow Gaussian distribution with mean 0 and vari-
ance 0.12 (coefficient of variance 10%). In contrast to the orig-
inal, Gen1 and Gen2, the two different formulations of gener-
ics (i.e., manufactured by two different companies) were also
assumed to be given to the same virtual patient. The AUC-
Gen symbols in the above equations were not given the sub-
script j because they were separately expressed in two differ-
ent equations, (4-1) and (4-2) by ε Gen1_i and ε Gen2_i. The ε Gen1_i
and ε Gen2_i had different variance (ω Gen12 and ω Gen22, respective-
ly) defined by each scenario. The time intervals between the
four events of drug administrations (twice for the original and
twice for the generics) per patient were assumed to be long
enough to ignore drug accumulation. No period or sequence
effect was assumed to exist.
Scenarios
The aim of the simulation was to compare the AUC changes
in each patient when he/she was given the original or one of
many generics. For all of the four scenarios (A, B, C, and D),
the Pop Mean AUC of the original formulation of Drug X
was fixed at 100. In scenarios A and B, the Pop Mean AUCs
of the generics were 90, 95, 105, and 110, with the RV either
being fixed at the same value (10%, scenario A) or being ran-
domly chosen from 1.0, 1.25 or 1.5 times (scenario B) that
of the original. More often than not, there may be several tens
of generics per original brand in the market. To reflect this,
scenario C had 30 generics, with Pop Mean AUC ranging
from 80 to 123.5, increasing by a factor of 1.5 but the RVs
fixed at 10%. Scenario D had Pop Mean AUCs identical to
those of scenario C, but the RV was randomly chosen between
10%, 12.5% and 15% (1.0, 1.25 or 1.5 times that of the orig-
inal), as in scenario B. The use of larger RV values for the ge-
nerics compared with that of the original (10%) in scenarios
B and D arose from the concern that the quality control ser-
vices of small-to-medium sized companies producing gener-
ics may not be as competent as those practiced in the com-
panies producing the originals. However, the Pop Mean AUC
ranges (80-123.5) in scenarios C and D were assumed to sat-
isfy the 90% confidence interval of BE guidances (80-125).
The four scenarios are summarized in Table 1.
Data generation
The models and scenarios were simulated using the R pro-
gram (Version 2.4.1, http://www.r-project.org/). For each virtu-
al patient, two AUCs were simulated after giving the original
on two separate occasions (AUCOri_i1 and AUCOri_i2), and the
next two AUCs after giving two different generics (AUCGen1_i
and AUCGen2_i) which were randomly selected from the gener-
ics of each scenario (e.g., selecting two different generics out
of 30 generics for scenario C). In other words, four AUC values
were generated per patient, who shared the same η i, but had
four different values of ε . The ε which includes intra-subject
variability, intra-formulation variability and other unknown
errors is changeable at every occasion. This process was repeat-
ed 5,000 times per scenario to mimic the situation of pre-
scription and dispensing for the equivalent number of patients. 
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*Between subject variability (BSV) η i~N (0, 0.2
2); 
� Residual variability (RV), including the variability coming from within-subject and within-formulation
differences. ε ~N (0, ω 2).
Scenario Original
Generic
Pop Mean AUC BSV* RV
�
(ω Gen value)
A 90, 95, 105, 110 0.1
B 90, 95, 105, 110 0.1, 0.125, 0.15
C 80, 81.5, 83, ..., 123.5  0.1
D 80, 81.5, 83, ..., 123.5  0.1, 0.125, 0.15
Same as original:
η i~N (0, 0.2
2)
Pop Mean AUC=100
BSV: η i~N (0, 0.2
2)
RV: ε Ori_ij~N (0, 0.1
2)
Table 1. Summary of scenarios A to DRESULTS
Scenarios A to D were sequentially run using the R pro-
gram. Each run of the scenario constructed data for 5,000 vir-
tual patients and four AUCs (two for the original, two for dif-
ferent generics) were simulated per patient.
AUC ratio of ‘Original to Original’
Before assessing the effect of drug switch, the ratio of two
original AUCs was calculated for each patient. This was to
estimate the fluctuation of the AUC when the same formu-
lation was given to the same patient without any drug switch-
in other words, it is a measure of the influence of RV only on
the AUC of each patient. In the top panel of Fig. 1, illustrating
the results of scenario D, the AUC ratio histogram of ‘origi-
nal to original’ (AUCOri_i2/AUCOri_i1, i=1-5,000th patient) is
given. The histograms in the other scenarios were almost iden-
tical because the model for the original formulation was the
same. As shown in the histogram, there were a lot of patients
who fell outside of the ratio 0.8-1.25, the equivalence win-
dow, in the course of repeated dosing of the original formu-
lation (4.9% of patients were <0.80, 6.2% of patients were
>1.25). However, the number of patients who had ratios small-
er than 0.67 or greater than 1.5 was negligible. When the
same simulation was performed with RV values greater than
10%, the proportion of patients outside of the BE window
increased accordingly (data not shown). However, the AUCOri_i2/
AUCOri_i1 histogram needs careful interpretation because it
indicates the degree of fluctuation of the AUC after each dos-
ing, and not the ultimate increase or decrease in the mean
steady state AUC, which stays constant since the patients
were given the same original formulation.
AUC ratios of ‘Original to Generic’
The AUC ratios (AUCGen1_i/AUCOri_i1) resulting from a switch
from the original formulation to a generic in the four scenar-
ios are summarized in Table 2. The two different generics
Simulation of Generic Substitution 9
Fig. 1. Simulation results of scenario D, one of the four scenarios.
Each histogram represents the AUC ratios of 5,000 virtual patients.
The generics in scenario D had a Pop Mean AUC ranging from
80-123.5 (original: 100) and an RV of 10-15% (original: 10%). The
proportion of patients falling outside of the ratio margin 0.67-1.5
(shaded zone) was also included. (A) The AUCs fluctuate even
when the same patient takes the same original formulation on two
occasions because of the RV value, given as 10% in this scenario.
(B) AUCGen1_i/AUCOri_i1 in the case of switch from the original to a
generic. (C) AUCGen1_i/AUCGen2_i in the case of switch from a generic
to another generic.
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Scenarios-characteristics of the generics on the market Simulation results
Sce-
nario
Remark
Number of  Pop Mean
generics AUC  of
RV
onthe generics
market (original=100)
When switched from  When switched from 
original to generic generic to another generic
(AUCGen1_i/AUCOri_i1) (AUCGen1_i/AUCGen2_i)
<0.67 >1.5 Subtotal <0.67 >1.5 Subtotal
A 4 90-110 Same as original 0.6% 0.7% 1.3% 1.4% 1.1% 2.5%
(90, 95, 105, 110) (10% of mean AUC)
B4  ( ×3) 1, 1.25, 1.5 times 1.3% 1% 2.3% 2.4% 3.3% 5.7%
original
C 30 80-123.5 Same as original
(even distribution (10% of mean AUC) 1.2% 1.8% 3% 4.5% 4.5% 9% Scenarios C and D
with 1.5 interval) may be more like real
D 30 (×3) 1, 1.25, 1.5 times 2.3% 2.3% 4.6% 6.1% 5.9% 12% situation than A and B. 
original
Table 2. Simulation results of four scenarios in 5,000 virtual patients. The proportion of patients who had an AUC ratio of less than 0.67
(2/3) or more than 1.5 after switching from ‘original to generic’ or ‘generic to another generic’ are given
A
B
Cgiven to each patient were randomly selected from those with
different Pop Mean AUCs and/or RVs defined in each sce-
nario. An arbitrarily determined safety range of 0.67 (AUC
decreased by more than 1/3 after switch) to 1.5 (AUC increased
by more than 1.5 times after switch) was used to estimate the
proportion of patients who may be harmed by the lack of effect
or by overdosing. Along with scenarios A to D, the propor-
tion of those outside of the safety range increased from 1.3%
to 4.6%.
AUC ratios of ‘Generic to another Generic’
When a patient taking a generic is switched to another
generic on the market, what happens to his/her AUC ? To
answer to this question, we also simulated the situation of
generic to generic switch in each scenario. The proportion of
patients who had simulated AUC ratios (AUCGen1_i/AUCGen2_i)
outside of the safety range 0.67-1.5 after ‘generic to another
generic’ switch (2.5-12% in different scenarios) were always
greater than the above ‘original to generic’ situation. In sce-
narios C and D, where the Mean Pop AUC ranges were greater
than those for scenarios A and B, there were more patients
outside of the safety range, as expected. The results are sum-
marized in Table 2.
DISCUSSION
Disputes on the safety of generic substitution have a long
history, with a lot of conflicting reports. Most of the papers
addressing the safety problem of generic substitution are case
reports on the therapeutic inequivalence caused by substitu-
tion. By contrast, the ‘pro-substitution’ papers have mainly
focused on the saving of medication costs in their own coun-
tries (10-13), without focusing on the additional costs that
may be incurred by therapeutic failure as a result of generic
substitution. Richton-Hewett et al. (14), however, measured
both the medication cost and healthcare cost after switching
branded warfarin to a generic in Boston City Hospital. In their
report, the healthcare cost increase from more frequent hos-
pital visits and elongation of the admission period caused by
generic substitution was greater than the medication cost
saved. Likewise, Hellstrom et al. (15) also showed an increas-
ing number of adverse effects with increasing market shares
of generics based on time-series data from 1972 to 1996. If
the pharmacokinetic results of generic substitution are to be
assessed, well-designed prospective studies are recommend-
ed. However, because it is not practical in clinical settings,
Rosenbaum et al. (16) detected 20-30% lower phenytoin
concentrations in generic formulation-treated patients than
in those treated with the original formulation (Dilantin
�) via
retrospective analysis of the therapeutic drug monitoring data.
Against this background, computer simulation is thought to
be an appropriate method to predict the changes in drug expo-
sure in a large patient population after generic substitution.
In simulation-based researches, a critical factor is the fideli-
ty or reliability of the model used to perform the simulation.
In our model, the distribution of Pop Mean AUC of gener-
ics had the strongest influence on the AUC ratios. There are
typically several tens of generics per original brand on the mar-
ket. It is impossible to know their mean AUC values and vari-
ance. BE study reports that contain such information are arc-
hived by companies and regulatory authorities but these are
not to be publicized. Hence, the BSV of 20% and the RV of
10-15% used in the present study were chosen for the con-
venience of simulation without regard to real BE data. How-
ever, the BSV does not influence the switch results as men-
tioned in the method section. When compared with the au-
thor’s experiences in several repeated-dosing PK studies, the
RV of 10-15% used herein may be a conservative condition,
i.e. switch results in the real world may be worse than the sim-
ulated ones in this report.
The AUC ratio histograms obtained by the simulation were
influenced by both the Pop Mean AUCs and their variability
(BSV and RV), as expected. In the model assumption, scenar-
ios C and D were given a broader range of Pop Mean AUC
(80-123.5) for the generics compared with scenarios A and
B. The shape of the Pop Mean AUC distribution was assumed
to be uniform (evenly distributed) with an interval of 1.5 in
scenarios C and D. The condition of uniform distribution as-
sumed herein may seem to be ‘unfair’ for the generic drugs,
since the estimate of the mean AUC ratio, which is equiva-
lent to the Pop Mean AUC for the generics in this report, is
known to be log-normally distributed with a 90% confidence
interval within the 80-125% range, but not uniform-distribut-
ed. However, at the same time, none of the scenarios in this
report had Pop Mean AUC values of the generics outside of
the 80-125% range, a situation which may occur with a prob-
ability of less than 10% (tails on both sides of the distribution
curve) in the case of ‘log-normal distribution’. Therefore, the
assumption of uniform distribution was not an unduly harsh
condition to make the AUC changes after generic switch seem
worse than they really are.
The safety range of the AUC ratio (0.67 to 1.5) used in this
study to estimate the proportion of patients falling outside of
this range was determined to help the readers to interpret the
AUC differences caused by switch. Although the limits of
0.67 and 1.5 may be somewhat arbitrary, the proportion out-
side of the cutoff range helps us to estimate the possibility of
therapeutic failure, especially for NTI drugs. In scenarios C
and D, it may be concluded that roughly 10% of patients may
experience therapeutic failure when substituted from one ge-
neric to another generic. Currently, not a country requests
BE studies comparing a generic with another generic, where
mean AUC and Cmax may differ by 45% in the most extreme
case (80% generic versus 125% generic). This is why the ‘gener-
ic to another generic’ switch was found more dangerous than
the ‘original to generic’ switch in this simulation study.
10 D.-S. YimAs with the simulation results herein, it is worth consid-
ering the surveys from patients who were exposed to gener-
ic substitution (from the original). In Norway, 36% of the
patients had one or more negative experiences after switch
(17). In Denmark, 6% of patients responded that he/she had
experienced more side-effects from the substituted medicine,
and 10% felt that the substituted medicine had had a weak-
er effect, although 85% of responders were positive about
the substitution policy itself (18). In Germany, 37% of patients
were skeptical towards generics because of their lower price
(19). Such concerns will be considerably amplified in Korea,
where a substantial proportion of marketed generics are sus-
pected to be of sub-standard quality. 
The problem of therapeutic inequivalence may be more
serious in those generics approved without BE tests. In many
countries, digestives, topical agents (creams, ointments etc.)
and other parenteral formulations are approved without human
PK studies. A case report of therapeutic failure by a generic
digestive followed by recovery after switch to the original
formulation (20) demonstrates that the therapeutic inequiv-
alence is not simply a theoretical possibility. The fact that 10
generic acyclovir creams were found to have a bioavailabili-
ty of less than 50% of that of the original formulation in in
vitro skin permeation experiments (21) also demonstrates the
need to tighten the regulatory web on the topical generics
approved without BE tests. Moreover, the quality of intra-
venous formulations also needs thorough examination to assure
their safety and quality. This necessity seems to be greater for
some macromolecule drugs, which tend to be harder to syn-
thesize and eliminate detrimental byproducts during the man-
ufacturing process.
Generic prescription or substitution has been widely prac-
ticed in the US and EU countries for the purpose of health-
care cost containment. In Ontario, Canada, mandatory gener-
ic substitution-a more decisive policy of giving patients gener-
ic drugs, regardless of the prescription-was introduced in 2003
(22). In 2007, however, it was reported that the proportion
of switching back to the original was higher for antiepileptic
agents, one of typical NTI drugs, than for other drugs. Alth-
ough the causes of switching back were not known, this report
implies that the safety and effect of generic substitution of
NTI drugs may not be guaranteed under mandatory gener-
ic substitution. The perspectives of pharmacists may be dif-
ferent, but they are unlikely to be free from concerns about
the safety of patients either. In France, where generic substi-
tution has been possible since 1999, pharmacists are satisfied
with the fact that they can exercise the ‘substitution right’
(23). However, only 42.5% of them were found to dispense
generics to patients routinely, and 55% did so to specific pa-
tients only (23) for many reasons including safety concerns.
A survey report from the US showing that many pharmacists
have negative opinions on the generic warfarin substitution
(24) is another example showing that pharmacists are also con-
cerned for the safety of NTI generics.
Through this simulation study, we were able to find that
a significant proportion of patients may be exposed to the
possibility of under-treatment or overdosing by the switch
of drugs, especially when switched from a generic to anoth-
er generic. In conclusion, the present report supports the old
notion that prescription drugs-especially the NTI drugs-should
be carefully chosen by physicians based on the consideration
of individual patient’s condition, not by the governmental
policy to save medication cost.
ACKNOWLEDGMENTS
A part of this manuscript was presented at BioKorea 2007
held in Seoul. The author is grateful to Prof. Sang-Goo Shin
and Kyung- Sang Yu at Seoul National University for their
invaluable advice and inspiration which were essential to the
execution of this in silico research. 
REFERENCES
1. Williams RL. Therapeutic equivalence of generic drugs: response to
National Association of Boards of Pharmacy. Available at: http:
//www.fda.gov/cder/news/ntiletter.htm [Accessed on Aug. 31, 2007].
2. Todd JS. Substitution of NTI drugs: physicians must maintain control.
J Med Assoc Ga 1997; 86: 121-3.
3. Ross MB. Status of generic substitution: problematic drug classes re-
viewed. Hosp Formul 1989; 24: 441-4, 447-9.
4. Brust M, Hawkins CF, Grayson D. Physicians’ attitudes toward gener-
ic drug substitution by pharmacists. Tex Med 1990; 86: 45-9.
5. Banahan BF 3rd, Kolassa EM. A physician survey on generic drugs
and substitution of critical dose medications. Arch Intern Med 1997;
157: 2080-8.
6. Burns M. Management of narrow therapeutic index drugs. J Thromb
Thrombolysis 1999; 7: 137-43.
7. Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS,
Barr WH. Drug substitution in transplantation: a National Kidney
Foundation White Paper. Am J Kidney Dis 1999; 33: 389-97.
8. Reiffel JA, Kowey PR. Generic antiarrhythmics are not therapeuti-
cally equivalent for the treatment of tachyarrhythmias. Am J Cardi-
ol 2000; 85: 1151-3, A10.
9. Reiffel JA. Issues in the use of generic antiarrhythmic drugs. Curr
Opin Cardiol 2001; 16: 23-9.
10. Sakshaug S, Furu K, Karlstad O, Ronning M, Skurtveit S. Switching
statins in Norway after new reimbursement policy-a nationwide pre-
scription study. Br J Clin Pharmacol 2007; 64: 476-81.
11. Beecroft G. Generic drug policy in Australia: a community pharmacy
perspective. Aust New Zealand Health Policy 2007; 4: 7.
12. Andersson K, Bergstrom G, Petzold MG, Carlsten A. Impact of a ge-
neric substitution reform on patients’ and society’s expenditure for
pharmaceuticals. Health Policy 2007; 81: 376-84.
13. Wasserfallen JB, Shimia S, Biollaz J, Pannatier A. Generic drug pre-
scribing: pilot study on the impact of the new drug pricing system on
Simulation of Generic Substitution 11costs and potential savings. Rev Med Suisse 2006; 2: 865-6, 868-71.
14. Richton-Hewett S, Foster E, Apstein CS. Medical and economic con-
sequences of a blinded oral anticoagulant brand change at a munic-
ipal hospital. Arch Intern Med 1988; 148: 806-8.
15. Hellstrom J, Rudholm N. Side effects of generic competition? Eur J
Health Econ 2004; 5: 203-8.
16. Rosenbaum DH, Rowan AJ, Tuchman L, French JA. Comparative
bioavailability of a generic phenytoin and Dilantin. Epilepsia 1994;
35: 656-60.
17. Kjoenniksen I, Lindbaek M, Granas AG. Patients’ attitudes towards
and experiences of generic drug substitution in Norway. Pharm World
Sci 2006; 28: 284-9.
18. Andersen ML, Laursen K, Schaumann M, Rubak SL, Olesgaard P,
Mainz J, Lauritzen T. How do patients evaluate the newly introduced
system of substituting prescriptions? Ugeskr Laeger 2000; 162: 6066-9.
19. Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen RD,
Kochen MM, Gleiter CH, Hummers-Pradier E. What do primary care
patients think about generic drugs? Int J Clin Pharmacol Ther 2005;
43: 472-9.
20. Hendeles L, Dorf A, Stecenko A, Weinberger M. Treatment failure
after substitution of generic pancrelipase capsules. Correlation with
in vitro lipase activity. JAMA 1990; 263: 2459-61.
21. Trottet L, Owen H, Holme P, Heylings J, Collin IP, Breen AP, Siyad
MN, Nandra RS, Davis AF. Are all aciclovir cream formulations bioe-
quivalent? Int J Pharm 2005; 304: 63-71.
22. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory gener-
ic switching of antiepileptic drugs: high switchback rates to branded
compounds compared with other drug classes. Epilepsia 2007; 48:
464-9.
23. Allenet B, Barry H. Opinion and behaviour of pharmacists towards
the substitution of branded drugs by generic drugs: survey of 1,000
French community pharmacists. Pharm World Sci 2003; 25: 197-202.
24. Bongiorno RA, Nutescu EA. Generic warfarin: implications for clini-
cal practice and perceptions of anticoagulation providers. Semin Th-
romb Hemost 2004; 30: 619-26.
12 D.-S. Yim